

DESCRIPTION

Source	Mouse myeloma cell line, NS0-derived			
	Human Ephrin-B1 (Lys30-Ser229) Accession # Q544L9	IEGRMD	Human IgG ₁ (Pro100-Lys330)	6-His tag
	N-terminus		C-terminus	

N-terminal Sequence Lys30

Analysis

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 49.2 kDa (monomer)

SPECIFICATIONS

SDS-PAGE 60 kDa, reducing conditions

Activity Measured by its binding ability in a functional ELISA.
Immobilized recombinant mouse EphB3 Fc Chimera at 2 µg/mL (100 µL/well) can bind biotinylated Recombinant Mouse Ephrin-B1 Fc Chimera with a linear range of 0.078-1.25 ng/mL.
Optimal dilutions should be determined by each laboratory for each application.

Purity >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute with sterile PBS at 100 µg/mL.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage **Use a manual defrost freezer and avoid repeated freeze-thaw cycles.**

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

Ephrin-B1, also known as Elk Ligand, LERK2, and Eplg2, is an approximately 45 kDa member of the Ephrin-B family of transmembrane ligands that bind and induce the tyrosine autophosphorylation of Eph receptors. The extracellular domains (ECD) of Ephrin-B ligands are structurally related to GPI-anchored Ephrin-A ligands. Eph-Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. Ephrin-B1 preferentially interacts with receptors in the EphB family. The binding of Ephrin-B1 to EphB proteins also triggers reverse signaling through Ephrin-B1 (1, 2). Mature mouse Ephrin-B1 consists of a 212 amino acid (aa) ECD, a 21 aa transmembrane segment, and an 88 aa cytoplasmic domain (3, 4). Within the ECD, mouse Ephrin-B1 shares 94% and 98% aa sequence identity with human and rat Ephrin-B1, respectively. Ligation by EphB2 enhances shedding of a 35 kDa fragment of the Ephrin-B1 ECD (5). The residual membrane-bound portion is then cleaved by gamma-secretase to release the intracellular domain (6). Ephrin-B1 also associates *in cis* with Claudin-1, -4, and -5 (7, 8). It is expressed on glomerular podocyte slit diaphragms, developing thymocytes, peripheral T cells, monocytes, macrophages, vascular endothelial cells, cardiomyocytes, osteoclasts, and luteinizing granulosa cells in the ovary (8-13). In the developing nervous system, Ephrin-B1 plays a role in cellular migration, axon guidance, and presynaptic development (14-16). It also regulates developing thymocyte survival, monocyte migration, osteoclast differentiation and function, cardiac muscle morphogenesis, and tumorigenesis (5, 8, 10-12). Ephrin-B1 is up-regulated on reactive astrocytes and on macrophages and T cells found in atherosclerotic plaques (11, 17).

References:

1. Miao, H. and B. Wang (2009) *Int. J. Biochem. Cell Biol.* **41**:762.
2. Pasquale, E.B. (2010) *Nat. Rev. Cancer* **10**:165.
3. Shao, H. *et al.* (1994) *J. Biol. Chem.* **269**:26606.
4. Fletcher, F.A. *et al.* (1994) *Genomics* **24**:127.
5. Tanaka, M. *et al.* (2007) *J. Cell Sci.* **120**:2179.
6. Tomita, T. *et al.* (2006) *Mol. Neurodegen.* **1**:2.
7. Tanaka, M. *et al.* (2005) *EMBO J.* **24**:3700.
8. Genet, G. *et al.* (2012) *Circ. Res.* **110**:688.
9. Hashimoto, T. *et al.* (2007) *Kidney Int.* **72**:954.
10. Yu, G. *et al.* (2006) *J. Biol. Chem.* **281**:10222.
11. Sakamoto, A. *et al.* (2008) *Clin. Sci.* **114**:643.
12. Cheng, S. *et al.* (2012) *PLoS ONE* **7**:e32887.
13. Egawa, M. *et al.* (2003) *J. Clin. Endocrinol. Metab.* **88**:4384.
14. Davy, A. *et al.* (2004) *Genes Dev.* **18**:572.
15. Bush, J.O. and P. Soriano (2009) *Genes Dev.* **23**:1586.
16. McClelland, A.C. *et al.* (2009) *Proc. Natl. Acad. Sci. USA* **106**:20487.
17. Wang, Y. *et al.* (2005) *Eur. J. Neurosci.* **21**:2336.